LRRC24: A Potential Drug Target and Biomarker for Various Diseases

Target Name: LRRC24

NCBI ID: G441381

LRRC24

Other Name(s): LRC24_HUMAN | Leucine-rich repeat-containing protein 24 | LRRC14OS | leucine rich repeat containing 24 | Leucine rich repeat containing 24

LRRC24: A Potential Drug Target and Biomarker for Various Diseases

LRRC24 is a protein that is expressed in various tissues of the human body, including the brain, heart, and kidneys. It is a member of the long non-coding RNA (lncRNA) family, which includes proteins that play important roles in various cellular processes. One of the unique features of LRRC24 is its ability to interact with other proteins, particularly the protein known as TCF7, which is a key regulator of the immune response and has been implicated in a number of diseases, including cancer.

Recent studies have identified LRRC24 as a potential drug target for the treatment of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This is because LRRC24 has been shown to play important roles in the development and progression of these diseases, and may be able to serve as a diagnostic or therapeutic target.

One of the reasons why LRRC24 is being targeted as a drug candidate is its ability to interact with TCF7. TCF7 is a transcription factor that plays a central role in the regulation of gene expression, and has been shown to play a key role in the development and progression of cancer. LRRC24 has been shown to interact with TCF7 and to regulate the activity of the transcription factor, which may contribute to its potential as a drug target.

Another reason why LRRC24 is being targeted as a drug candidate is its role in the development of neurodegenerative diseases. Neurodegenerative diseases are a group of disorders that are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles. LRRC24 has been shown to play important roles in the development and progression of these diseases, and may be able to serve as a diagnostic or therapeutic target.

For example, studies have shown that LRRC24 is expressed in the brains of individuals with Alzheimer's disease, a neurodegenerative disease that is characterized by the progressive loss of brain cells and the formation of neurofibrillary tangles. Additionally, LRRC24 has been shown to interact with the protein known as beta-amyloid, which is a hallmark of neurodegenerative disease and has been shown to contribute to the development and progression of these diseases.

LRRC24 may also be a useful biomarker for the diagnosis and prognosis of neurodegenerative diseases. For example, studies have shown that LRRC24 is expressed in the brains of individuals with Parkinson's disease, a neurodegenerative disease that is characterized by the progressive loss of brain cells and the formation of neurofibrillary tangles. Additionally, LRRC24 has been shown to interact with the protein known as dopamine, which is a neurotransmitter that is involved in the treatment of Parkinson's disease.

In addition to its potential as a drug target and biomarker, LRRC24 is also being studied for its potential role in the regulation of immune responses. Studies have shown that LRRC24 is expressed in the immune cells of individuals and that it plays important roles in the regulation of the immune response. This may suggest that LRRC24 may be a useful target for the treatment of autoimmune disorders.

Overall, LRRC24 is a protein that has the potential to be a drug target and biomarker for the treatment of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Further research is needed to fully understand the role of LRRC24 in these diseases and to develop effective treatments.

Protein Name: Leucine Rich Repeat Containing 24

The "LRRC24 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LRRC24 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets